logo
Plus   Neg
Share
Email

Addex To Get $330 Mln Potential Milestones In Licensing Deal With Indivior

Switzerland-based Addex Therapeutics announced Wednesday the signing of a licensing and collaboration agreement with Indivior PLC (INDV.L) for global development and commercialization of ADX71441 for the treatment of addiction.

Under the terms of the agreement, Addex will receive $5 million upfront, $4 million of committed research funding over the next two years, $330 million of potential development, regulatory and commercialization milestones and tiered royalties up to double-digit.

Addex retains the right to select compounds from the research collaboration for certain indications outside addiction, including Charcot-Marie-Tooth type 1a neuropathy or CMT1A.

ADX71441 is a potent, selective positive allosteric modulator or PAM that potentiates GABA responses at the GABAB receptor. In addition, Indivior will fund a research program at Addex to discover additional GABAB PAM compounds.

Tim Dyer, CEO at Addex, said, "This agreement is part of our ongoing strategy to secure resources to advance certain assets of our broad allosteric modulator pipeline with leading players in key markets."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The takeover battle by Comcast Corp. nd Rupert Murdoch's 21st Century Fox Inc. for British broadcaster Sky plc will be settled through an auction. The UK Takeover Panel said Thursday that an auction procedure is expected to commence on the evening of Friday, September 21, 2018 and end on the evening of September 22, 2018. The winner of the auction will be announced on Saturday. Luxury car maker Aston Martin on Thursday announced the pricing range for its planned initial public offering on the London Stock Exchange, valuing the company at up to $6.7 billion. The UK-based maker of the famed car favored by iconic spy James Bond, has set the price range for its IPO at 17.50 pounds to 22.50 pounds per ordinary share. Alibaba's founder and chairman Jack Ma has said that the Chinese e-commerce giant no longer plans to create 1 million jobs in the US, citing the ongoing trade conflict between the US and China as the reason. "The promise was made on the premise of friendly US-China partnership and rational trade relations,"...
Follow RTT